Vertex Pharmaceuticals

VRTXNASDAQ

Disease-focused small molecules, cell therapy, and gene-editing partnerships

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

Filing figures as of June 30, 2026 · text updated 2026-04-09, 222 days ago · where each field comes from

Key figures from SEC filings

VRTX filings on EDGAR →

Cash & investments

$13.64B

at June 30, 2026 (10-Q)

Quarterly operating burn

No burn

operating cash flow positive, Jan–Jun 2026

Cash runway

—

not a runway: funded by operations

Shares outstanding

253.5M

cover page of the latest filing

Read from VRTX's XBRL financial data; latest filing August 4, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Commercial.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

Suzetrigine DPN Phase 3: Suzetrigine in Pain associated with diabetic peripheral neuropathy — primary completion

2027-05-31

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Suzetrigine DPN open-label extension: Suzetrigine in Diabetic peripheral neuropathic pain — primary completion

2027-01-25

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

ELX/TEZ/IVA non-F508del: Elexacaftor/tezacaftor/ivacaftor in Cystic fibrosis, non-F508del genotypes — primary completion

2027-04-06

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
Trikaftacystic fibrosisApprovedNot disclosed▼
Suzetrigineacute and neuropathic painNDA/BLA FiledNot disclosed▼
Casgevysickle cell disease and transfusion-dependent beta thalassemiaApprovedNot disclosed▼

Analysis

We have not yet written an analysis of Vertex Pharmaceuticals that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade VRTX commission-free on Webullvia Webull · Affiliate

Comparable companies

Regeneron PharmaceuticalsAlnylam PharmaceuticalsCRISPR Therapeutics

Sponsored

Get premium VRTX analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Vertex Pharmaceuticals has 156 Phase 2 or 3 studies on ClinicalTrials.gov: 115 completed, 17 stopped early, 24 ongoing.

115

Completed

17

Stopped early

24

Ongoing

Stopped early

  • NCT05951205Phase 3 · started 2027 · withdrawn

    Exa-cel in sickle cell disease · n=0

    Reason given: Modification to the clinical development plan

  • NCT05643495Phase 2 · started 2023 · terminated

    VX-864 in alpha-1 antitrypsin deficiency · n=14

    Reason given: Study drug dosing was permanently discontinued at the Sponsor's discretion based on frequency and nature of skin and subcutaneous tissue disorders.

  • NCT04167345Phase 2 · started 2020 · terminated

    VX-814 in alpha 1-antitrypsin deficiency · n=48

    Reason given: at Sponsor's discretion

  • NCT03633526Phase 3 · started 2018 · terminated

    VX-659/TEZ/IVA in cystic fibrosis · n=18

    Reason given: Study discontinued after Part A due to Sponsor's discretion.

  • NCT03447262Phase 3 · started 2018 · terminated

    VX-659/TEZ/IVA in cystic fibrosis · n=484

    Reason given: At Sponsor's Discretion

  • NCT02971839Phase 2 · started 2016 · terminated

    VX-561 in cystic fibrosis · n=11

    Reason given: Decision by Sponsor.

  • NCT02669849Phase 2/3 · started 2016 · terminated

    VX-210 in cervical spinal cord injury · n=70

    No reason recorded in the registry.

  • NCT02742519Phase 3 · started 2016 · terminated

    ivacaftor in cystic fibrosis · n=14

    Reason given: Low enrollment.

  • NCT01701063Phase 1/2 · started 2013 · terminated

    Telaprevir in hepatitis c · n=42

    No reason recorded in the registry.

  • NCT01467505Phase 2 · started 2012 · terminated

    Telaprevir in hepatitis c · n=61

    Reason given: The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.

  • NCT01467479Phase 3 · started 2011 · terminated

    Telaprevir in hepatitis c · n=185

    Reason given: It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy endpoint as part of a decision to modify drug development plan.

  • NCT01501383Phase 2 · started 2011 · terminated

    VX-765 Part A in epilepsy · n=55

    Reason given: Terminated by Sponsor

  • CONCISEPhase 3 · started 2011 · terminated

    Telaprevir in hepatitis c, chronic · n=239

    Reason given: The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.

  • NCT01080222Phase 2 · started 2010 · terminated

    telaprevir in chronic hepatitis c virus infection · n=152

    Reason given: Study discontinued

  • DISCOVERPhase 2 · started 2009 · terminated

    Ivacaftor in cystic fibrosis · n=140

    Reason given: Following review of results obtained from a pre-specified 6-month analysis of Part B data the study was terminated on the basis of futility.

  • NCT00493441Phase 2 · started 2007 · terminated

    AVN944 in pancreatic cancer · n=28

    No reason recorded in the registry.

  • NCT00003847Phase 2 · started 1998 · terminated

    biricodar dicitrate in lung cancer · n=36

    No reason recorded in the registry.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.